Yen‐Shen Lu
About
Yen‐Shen Lu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research.
According to data from OpenAlex, Yen‐Shen Lu has authored 238 papers receiving a total of 6.5k indexed citations (citations by other indexed papers that have themselves been cited), including 139 papers in Oncology, 115 papers in Pulmonary and Respiratory Medicine and 62 papers in Cancer Research. Recurrent topics in Yen‐Shen Lu's work include Advanced Breast Cancer Therapies (80 papers), Cancer Treatment and Pharmacology (58 papers) and HER2/EGFR in Cancer Research (48 papers). Yen‐Shen Lu is often cited by papers focused on Advanced Breast Cancer Therapies (80 papers), Cancer Treatment and Pharmacology (58 papers) and HER2/EGFR in Cancer Research (48 papers). Yen‐Shen Lu collaborates with scholars based in Taiwan, United States and South Korea. Yen‐Shen Lu's co-authors include Ann‐Lii Cheng, Ching‐Hung Lin, Chiun‐Sheng Huang, Fabrice André, Kenichi Inoue, Gábor Rubovszky, Hope S. Rugo, Zsuzsanna Pápai, Toshinari Yamashita and Bella Kaufman and has published in prestigious journals such as New England Journal of Medicine, Journal of Biological Chemistry and Journal of Clinical Oncology.
In The Last Decade
Yen‐Shen Lu
222 papers receiving 6.4k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Yen‐Shen Lu Taiwan | 36 | 3.3k | 2.6k | 2.3k | 2.1k | 754 | 238 | 6.5k | ||
| Martin Filipits Austria | 48 | 4.3k 1.3× | 3.1k 1.2× | 2.9k 1.3× | 2.7k 1.3× | 587 0.8× | 200 | 8.0k | ||
| Daniele Generali Italy | 42 | 3.1k 0.9× | 1.7k 0.6× | 2.5k 1.1× | 2.1k 1.0× | 404 0.5× | 232 | 6.2k | ||
| Jennifer J. Wheler United States | 42 | 2.6k 0.8× | 1.8k 0.7× | 3.2k 1.4× | 2.1k 1.0× | 446 0.6× | 199 | 6.7k | ||
| Dick J. Richel Netherlands | 43 | 4.5k 1.4× | 1.7k 0.6× | 3.5k 1.5× | 2.2k 1.0× | 462 0.6× | 107 | 9.6k | ||
| Lianchun Xiao United States | 49 | 3.0k 0.9× | 2.6k 1.0× | 2.8k 1.2× | 1.8k 0.9× | 334 0.4× | 214 | 7.9k | ||
| Miguel A. Villalona‐Calero United States | 43 | 3.2k 1.0× | 2.1k 0.8× | 2.7k 1.2× | 1.1k 0.5× | 359 0.5× | 187 | 6.4k | ||
| Gideon M. Blumenthal United States | 47 | 4.0k 1.2× | 2.6k 1.0× | 2.4k 1.1× | 1.3k 0.6× | 433 0.6× | 119 | 7.5k | ||
| Bijoyesh Mookerjee United States | 30 | 3.7k 1.1× | 2.2k 0.9× | 4.1k 1.8× | 2.3k 1.1× | 533 0.7× | 85 | 7.4k | ||
| Barbara A. Conley United States | 39 | 2.7k 0.8× | 1.5k 0.6× | 2.3k 1.0× | 1.3k 0.6× | 319 0.4× | 143 | 6.0k | ||
| Violeta Serra Spain | 36 | 3.1k 0.9× | 1.6k 0.6× | 4.2k 1.8× | 1.0k 0.5× | 742 1.0× | 92 | 7.5k |
Countries citing papers authored by Yen‐Shen Lu
Since
Specialization
Citations
This map shows the geographic impact of Yen‐Shen Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yen‐Shen Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yen‐Shen Lu more than expected).
Fields of papers citing papers by Yen‐Shen Lu
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Yen‐Shen Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yen‐Shen Lu. The network helps show where Yen‐Shen Lu may publish in the future.
Co-authorship network of co-authors of Yen‐Shen Lu
This figure shows the co-authorship network connecting the top 25 collaborators of Yen‐Shen Lu. A scholar is included among the top collaborators of Yen‐Shen Lu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yen‐Shen Lu. Yen‐Shen Lu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Cheng, Chun‐Wen, Yu‐Fan Liu, Wen‐Ling Liao, et al.. (2024). miR-622 Increases miR-30a Expression through Inhibition of Hypoxia-Inducible Factor 1α to Improve Metastasis and Chemoresistance in Human Invasive Breast Cancer Cells. Cancers. 16(3). 657–657.
2.
Pernas, Sònia, Seock‐Ah Im, Masaya Hattori, et al.. (2024). Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Patient-reported outcomes (PROs) from the TROPION-Breast01 study.. Journal of Clinical Oncology. 42(16_suppl). 1006–1006.
3.
Im, Seock‐Ah, Shoei‐Shen Wang, Yen‐Shen Lu, et al.. (2024). PS3-1 Dato-DXd vs. chemotherapy for patients with inoperable/metastatic HR+/HER2− breast cancer: TROPION-Breast01 Asian subset. Annals of Oncology. 35. S1314–S1314.
4.
Lin, Zhong‐Zhe, Mickey C.‐T. Hu, Chiun Hsu, et al.. (2023). Synergistic efficacy of telomerase-specific oncolytic adenoviral therapy and histone deacetylase inhibition in human hepatocellular carcinoma. Cancer Letters. 556. 216063–216063.
5.
Huang, Meng‐Chuan, I‐Chun Chen, Tsu‐Nai Wang, et al.. (2023). Lifestyle Factors and Energy Intakes with Risks of Breast Cancer among Pre- and Post- Menopausal Women in Taiwan. Nutrients. 15(18). 3900–3900.
6.
Hu, Xingjiang, Qingfu Zhang, Tao Sun, et al.. (2023). LBA5 Capivasertib (C) + fulvestrant (F) for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2– advanced breast cancer (ABC): Phase III CAPItello-291 trial Chinese cohort. Annals of Oncology. 34. S1485–S1486.
7.
Eralp, Yeşim, Hikmat Abdel‐Razeq, S-A. Im, et al.. (2023). 456P Quality of life (QOL) analysis from the phase II RIGHT choice study of first-line ribociclib (RIB) + endocrine therapy (ET) vs combination chemotherapy (combo CT) in aggressive HR+/HER2− advanced breast cancer (ABC). Annals of Oncology. 34. S372–S373.
8.
Azim, Hamdy A., Nagi S. El Saghir, Yoon Sim Yap, et al.. (2023). 402P First-line ribociclib (RIB) + endocrine therapy (ET) vs combination chemotherapy (combo CT) in aggressive HR+/HER2− advanced breast cancer (ABC): A subgroup analysis of patients (pts) with or without visceral crisis from the phase II RIGHT choice study. Annals of Oncology. 34. S350–S351.
9.
Lien, Huang‐Chun, Chia‐Lang Hsu, Yen‐Shen Lu, et al.. (2023). Transcriptomic alterations underlying metaplasia into specific metaplastic components in metaplastic breast carcinoma. Breast Cancer Research. 25(1). 11–11.
10.
Ma, Weili, Dwan‐Ying Chang, Ching‐Hung Lin, et al.. (2022). Clinical Outcomes of Metastatic Breast Cancer in Patients Having Imaging Liver Pseudocirrhosis with or without Evident Varices. The Oncologist. 27(12). 1008–1015.
11.
Lin, Ching‐Hung, Muhammad Zahid, Wen‐Hung Kuo, et al.. (2022). Estrogen-DNA Adducts and Breast Cancer Risk in Premenopausal Asian Women. Cancer Prevention Research. 16(3). 153–161.
12.
Lin, Ching‐Hung, Ruby Yun‐Ju Huang, Tzu‐Pin Lu, et al.. (2021). High prevalence of APOA1/C3/A4/A5 alterations in luminal breast cancers among young women in East Asia. npj Breast Cancer. 7(1). 88–88.
13.
André, Fabrice, Eva Ciruelos, Gábor Rubovszky, et al.. (2019). Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer. New England Journal of Medicine. 380(20). 1929–1940.
14.
Iwata, Hiroji, Norikazu Masuda, Sung‐Bae Kim, et al.. (2019). Neratinib After Trastuzumab-Based Adjuvant Therapy in Patients from Asia with Early Stage HER2-Positive Breast Cancer. Future Oncology. 15(21). 2489–2501.
15.
Lu, Yen‐Shen, Tom Wei‐Wu Chen, Ching‐Hung Lin, et al.. (2015). Bevacizumab Preconditioning Followed by Etoposide and Cisplatin Is Highly Effective in Treating Brain Metastases of Breast Cancer Progressing from Whole-Brain Radiotherapy. Clinical Cancer Research. 21(8). 1851–1858.
16.
Tripathy, Debu, Aditya Bardia, Sara A. Hurvitz, et al.. (2015). Phase III, randomized, double-blind, placebo-controlled study of ribociclib (LEE011) in combination with either tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with HR+, HER2- advanced breast cancer (aBC): MONALEESA-7.. Journal of Clinical Oncology. 33.
17.
Kuo, Sung‐Hsin, Shi‐Yi Yang, Huang‐Chun Lien, et al.. (2013). CYP19Genetic Polymorphism HaplotypeAASAIs Associated with a Poor Prognosis in Premenopausal Women with Lymph Node-Negative, Hormone Receptor-Positive Breast Cancer. BioMed Research International. 2013. 1–9.
18.
Lin, Po‐Han, et al.. (2011). Cisplatin as an active treatment in zoledronate-refractory hypercalcemia. Annals of Oncology. 22(5). 1244–1246.
19.
Ou, Da‐Liang, Ying‐Chun Shen, Ja‐Der Liang, et al.. (2009). Induction of Bim Expression Contributes to the Antitumor Synergy Between Sorafenib and Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase Inhibitor CI-1040 in Hepatocellular Carcinoma. Clinical Cancer Research. 15(18). 5820–5828.
20.
Lu, Yen‐Shen, et al.. (2006). Glucocorticoids enhance cytotoxicity of cisplatin via suppression of NF-κB activation in the glucocorticoid receptor-rich human cervical carcinoma cell line SiHa. Journal of Endocrinology. 188(2). 311–319.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Martin Filipits Breakdown of academic impact, for papers by Daniele Generali Breakdown of academic impact, for papers by Jennifer J. Wheler Breakdown of academic impact, for papers by Dick J. Richel Breakdown of academic impact, for papers by Lianchun Xiao Breakdown of academic impact, for papers by Miguel A. Villalona‐Calero Breakdown of academic impact, for papers by Gideon M. Blumenthal Breakdown of academic impact, for papers by Bijoyesh Mookerjee Breakdown of academic impact, for papers by Barbara A. Conley Breakdown of academic impact, for papers by Violeta Serra